Alpelisib is an oral selective inhibitor of the alpha subunit of PI3K indicated for postmenopausal women, and men, with advanced or metastatic HR + HER2- breast cancer harboring PI3K mutations. This evidence concerns the gene ERBB2 and breast cancer.